Advertisement

Topics

Novartis MONALEESA─7 trial of Kisqali in advanced/metastatic breast cancer meets primary endpoint

08:51 EST 9 Nov 2017 | PharmaBiz

Novartis announced positive topline results from the global MONALEESA─7 trial, the second phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer. The MONALEESA─7 trial met its

Original Article: Novartis MONALEESA─7 trial of Kisqali in advanced/metastatic breast cancer meets primary endpoint

NEXT ARTICLE

More From BioPortfolio on "Novartis MONALEESA─7 trial of Kisqali in advanced/metastatic breast cancer meets primary endpoint"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...